141 related articles for article (PubMed ID: 12540035)
1. Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits.
Klimtová I; Simůnek T; Mazurová Y; Hrdina R; Gersl V; Adamcová M
Hum Exp Toxicol; 2002 Dec; 21(12):649-57. PubMed ID: 12540035
[TBL] [Abstract][Full Text] [Related]
2. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
4. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
[TBL] [Abstract][Full Text] [Related]
5. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
[TBL] [Abstract][Full Text] [Related]
6. [Effects of new antineoplastic agents (dimethoxybenflurone and Oracin) on the cardiovascular system and other parameters in the rabbit in vivo].
Machácková J; Gersl V; Adamcová M; Mazurová Y; Hrdina R; Mĕlka M; Nobilis M
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):119-38. PubMed ID: 11413675
[TBL] [Abstract][Full Text] [Related]
7. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.
Simůnek T; Klimtová I; Kaplanová J; Sterba M; Mazurová Y; Adamcová M; Hrdina R; Gersl V; Ponka P
Pharmacol Res; 2005 Mar; 51(3):223-31. PubMed ID: 15661572
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane.
Hrdina R; Gersl V; Klimtová I; Simůnek T; Mazurová Y; Machácková J; Adamcová M
Acta Medica (Hradec Kralove); 2002; 45(3):99-105. PubMed ID: 12515046
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Gersl V; Bajgar J; Hrdina R; Mazurová Y; Machácková J; Cerman J; Suba P
Gen Physiol Biophys; 1999 Dec; 18(4):335-46. PubMed ID: 10766032
[TBL] [Abstract][Full Text] [Related]
10. Changes in cholinesterase activities after daunorubicin administration to rabbits.
Gersl V; Bajgar J; Krs O; Hrdina R; Palicka V; Mazurová Y
Hum Exp Toxicol; 1996 Oct; 15(10):834-8. PubMed ID: 8906433
[TBL] [Abstract][Full Text] [Related]
11. IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits.
Gersl V; Cerman J; Suba P; Mazurová Y; Hrdina R; Machácková J
Hum Exp Toxicol; 1999 Mar; 18(3):154-61. PubMed ID: 10215105
[TBL] [Abstract][Full Text] [Related]
12. Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy.
Simůnek T; Klimtová I; Adamcová M; Gersl V; Hrdina R; Sterba M; Kaplanová J; Mazurová Y
Cancer Chemother Pharmacol; 2003 Nov; 52(5):431-4. PubMed ID: 14618274
[TBL] [Abstract][Full Text] [Related]
13. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.
Suzuki T; Minamide S; Iwasaki T; Yamamoto H; Kanda H
Invest New Drugs; 1997; 15(3):219-25. PubMed ID: 9387044
[TBL] [Abstract][Full Text] [Related]
15. Protein profiling in daunorubicin-induced cardiomyopathy.
Adamcová M; Pelouch V; Gersl V; Kaplanová J; Mazurová Y; Simůnek T; Klimtová I; Hrdina R
Gen Physiol Biophys; 2003 Sep; 22(3):411-9. PubMed ID: 14986890
[TBL] [Abstract][Full Text] [Related]
16. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
17. Selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Christiansen S; Perez-Bouza A; Schälte G; Hilgers RD; Autschbach R
J Heart Lung Transplant; 2008 Jan; 27(1):86-92. PubMed ID: 18187092
[TBL] [Abstract][Full Text] [Related]
18. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits.
Adamcová M; Potáčová A; Popelová O; Štěrba M; Mazurová Y; Aupperle H; Geršl V
Physiol Res; 2010; 59(5):831-836. PubMed ID: 20406046
[TBL] [Abstract][Full Text] [Related]
19. An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy.
Talavera J; Giraldo A; Fernández-Del-Palacio MJ; García-Nicolás O; Seva J; Brooks G; Moraleda JM
Biomed Res Int; 2015; 2015():465342. PubMed ID: 26788502
[TBL] [Abstract][Full Text] [Related]
20. [Metilin Improves Сardiac Function in Rabbits With Chronic Heart Failure].
Studneva IM; Lakomkin VL; Veselova OM; Prosvirnin AV; Abramov AA; Pavlovich ER; Lubimov RO; Gramovich VV; Vyborov ON; Pisarenko OI; Kapelko VI
Kardiologiia; 2018 Jul; 58(7):66-74. PubMed ID: 30081811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
